annual cash & cash equivalents:
$10.86B-$1.48B(-11.97%)Summary
- As of today (August 26, 2025), BMY annual cash & cash equivalents is $10.86 billion, with the most recent change of -$1.48 billion (-11.97%) on December 31, 2024.
- During the last 3 years, BMY annual cash & cash equivalents has fallen by -$6.50 billion (-37.45%).
- BMY annual cash & cash equivalents is now -37.45% below its all-time high of $17.36 billion, reached on December 31, 2021.
Performance
BMY Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$13.62B+$1.83B(+15.57%)Summary
- As of today (August 26, 2025), BMY quarterly cash & cash equivalents is $13.62 billion, with the most recent change of +$1.83 billion (+15.57%) on June 30, 2025.
- Over the past year, BMY quarterly cash & cash equivalents has increased by +$6.96 billion (+104.61%).
- BMY quarterly cash & cash equivalents is now -58.16% below its all-time high of $32.54 billion, reached on September 30, 2019.
Performance
BMY quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
BMY Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -12.0% | +104.6% |
| 3 y3 years | -37.5% | +1.5% |
| 5 y5 years | -29.4% | -37.8% |
BMY Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -37.5% | +15.5% | at high | +104.6% |
| 5 y | 5-year | -37.5% | +15.5% | -37.8% | +104.6% |
| alltime | all time | -37.5% | +2429.5% | -58.2% | +2570.0% |
BMY Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $13.62B(+15.6%) |
| Mar 2025 | - | $11.78B(+8.5%) |
| Dec 2024 | $10.86B(-12.0%) | $10.86B(+34.1%) |
| Sep 2024 | - | $8.10B(+21.7%) |
| Jun 2024 | - | $6.66B(-31.2%) |
| Mar 2024 | - | $9.67B(-21.6%) |
| Dec 2023 | $12.34B(+31.2%) | $12.34B(+59.4%) |
| Sep 2023 | - | $7.74B(-11.9%) |
| Jun 2023 | - | $8.78B(-5.8%) |
| Mar 2023 | - | $9.32B(-0.8%) |
| Dec 2022 | $9.40B(-45.8%) | $9.40B(+2.3%) |
| Sep 2022 | - | $9.19B(-31.5%) |
| Jun 2022 | - | $13.42B(-12.6%) |
| Mar 2022 | - | $15.35B(-11.6%) |
| Dec 2021 | $17.36B(+5.0%) | $17.36B(+8.8%) |
| Sep 2021 | - | $15.96B(+12.5%) |
| Jun 2021 | - | $14.19B(+6.9%) |
| Mar 2021 | - | $13.28B(-19.7%) |
| Dec 2020 | $16.54B(+7.4%) | $16.54B(-22.6%) |
| Sep 2020 | - | $21.36B(-2.4%) |
| Jun 2020 | - | $21.88B(+19.4%) |
| Mar 2020 | - | $18.32B(+19.0%) |
| Dec 2019 | $15.39B(+73.3%) | $15.39B(-52.7%) |
| Sep 2019 | - | $32.54B(+10.8%) |
| Jun 2019 | - | $29.36B(+235.0%) |
| Mar 2019 | - | $8.76B(-1.4%) |
| Dec 2018 | $8.88B(+30.4%) | $8.88B(+30.1%) |
| Sep 2018 | - | $6.83B(+12.4%) |
| Jun 2018 | - | $6.08B(-10.3%) |
| Mar 2018 | - | $6.77B(-0.6%) |
| Dec 2017 | $6.81B(+7.3%) | $6.81B(-4.4%) |
| Sep 2017 | - | $7.12B(+9.5%) |
| Jun 2017 | - | $6.50B(+6.5%) |
| Mar 2017 | - | $6.11B(-3.8%) |
| Dec 2016 | $6.35B(+48.7%) | $6.35B(+14.2%) |
| Sep 2016 | - | $5.56B(+19.5%) |
| Jun 2016 | - | $4.65B(+8.0%) |
| Mar 2016 | - | $4.31B(+0.9%) |
| Dec 2015 | $4.27B(-42.6%) | $4.27B(-21.1%) |
| Sep 2015 | - | $5.41B(-1.2%) |
| Jun 2015 | - | $5.48B(-28.0%) |
| Mar 2015 | - | $7.61B(+2.3%) |
| Dec 2014 | $7.43B(+64.3%) | $7.43B(+3.0%) |
| Sep 2014 | - | $7.22B(+0.6%) |
| Jun 2014 | - | $7.17B(+1.6%) |
| Mar 2014 | - | $7.06B(+56.0%) |
| Dec 2013 | $4.53B(+60.0%) | $4.53B(+66.2%) |
| Sep 2013 | - | $2.72B(-2.8%) |
| Jun 2013 | - | $2.80B(+10.5%) |
| Mar 2013 | - | $2.53B(-10.5%) |
| Dec 2012 | $2.83B(-67.6%) | $2.83B(-3.4%) |
| Sep 2012 | - | $2.93B(-41.8%) |
| Jun 2012 | - | $5.04B(+0.2%) |
| Mar 2012 | - | $5.03B(-42.4%) |
| Dec 2011 | $8.73B(+19.6%) | $8.73B(+6.6%) |
| Sep 2011 | - | $8.19B(+6.8%) |
| Jun 2011 | - | $7.67B(+12.9%) |
| Mar 2011 | - | $6.79B(-7.0%) |
| Dec 2010 | $7.30B(-14.2%) | $7.30B(-12.7%) |
| Sep 2010 | - | $8.36B(+12.1%) |
| Jun 2010 | - | $7.45B(+10.0%) |
| Mar 2010 | - | $6.78B(-20.4%) |
| Dec 2009 | $8.51B(+3.0%) | $8.51B(+27.7%) |
| Sep 2009 | - | $6.67B(-17.9%) |
| Jun 2009 | - | $8.12B(-9.0%) |
| Mar 2009 | - | $8.92B(+7.9%) |
| Dec 2008 | $8.27B(+271.5%) | $8.27B(+11.2%) |
| Sep 2008 | - | $7.43B(+68.8%) |
| Jun 2008 | - | $4.40B(+66.9%) |
| Mar 2008 | - | $2.64B(+18.5%) |
| Dec 2007 | $2.23B | $2.23B(-37.9%) |
| Sep 2007 | - | $3.58B(-22.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2007 | - | $4.65B(+15.8%) |
| Mar 2007 | - | $4.01B(-0.0%) |
| Dec 2006 | $4.01B(-30.8%) | $4.01B(-27.1%) |
| Sep 2006 | - | $5.50B(+2.8%) |
| Jun 2006 | - | $5.36B(+1.4%) |
| Mar 2006 | - | $5.28B(-8.9%) |
| Dec 2005 | $5.80B(+4.3%) | $5.80B(+53.4%) |
| Sep 2005 | - | $3.78B(+24.4%) |
| Jun 2005 | - | $3.04B(-49.2%) |
| Mar 2005 | - | $5.98B(-17.5%) |
| Sep 2004 | - | $7.25B(+6.0%) |
| Jun 2004 | - | $6.84B(+3.4%) |
| Mar 2004 | - | $6.62B(+31.3%) |
| Dec 2003 | $5.56B(+39.4%) | - |
| Sep 2003 | - | $5.04B(+14.0%) |
| Jun 2003 | - | $4.42B(+1.7%) |
| Mar 2003 | - | $4.35B(+20.9%) |
| Dec 2002 | $3.99B(-29.4%) | - |
| Sep 2002 | - | $3.60B(-0.6%) |
| Jun 2002 | - | $3.62B(+1.1%) |
| Mar 2002 | - | $3.58B(+16.2%) |
| Dec 2001 | $5.65B(+67.0%) | - |
| Sep 2001 | - | $3.08B(-2.2%) |
| Jun 2001 | - | $3.15B(+7.2%) |
| Mar 2001 | - | $2.94B(-0.9%) |
| Dec 2000 | $3.38B(+14.5%) | - |
| Sep 2000 | - | $2.96B(+22.2%) |
| Jun 2000 | - | $2.42B(-9.6%) |
| Mar 2000 | - | $2.68B(-0.4%) |
| Dec 1999 | $2.96B(+16.9%) | - |
| Sep 1999 | - | $2.69B(+14.6%) |
| Jun 1999 | - | $2.35B(+2.8%) |
| Mar 1999 | - | $2.28B(+24.1%) |
| Dec 1998 | $2.53B(+29.2%) | - |
| Sep 1998 | - | $1.84B(+40.1%) |
| Jun 1998 | - | $1.31B(-30.3%) |
| Mar 1998 | - | $1.89B(-4.2%) |
| Sep 1997 | - | $1.97B(+5.0%) |
| Jun 1997 | - | $1.88B(-18.5%) |
| Mar 1997 | - | $2.30B(+21.9%) |
| Sep 1996 | - | $1.89B(+16.9%) |
| Jun 1996 | - | $1.61B(-10.6%) |
| Mar 1996 | - | $1.81B(+9.8%) |
| Dec 1995 | - | $1.65B(-1.7%) |
| Sep 1995 | - | $1.67B(-2.6%) |
| Jun 1995 | - | $1.72B(-2.7%) |
| Mar 1995 | - | $1.77B(+7.6%) |
| Dec 1994 | - | $1.64B(-10.9%) |
| Sep 1994 | - | $1.84B(-16.2%) |
| Jun 1994 | - | $2.20B(-12.8%) |
| Mar 1994 | - | $2.52B(+4.2%) |
| Dec 1993 | - | $2.42B(+4.0%) |
| Sep 1993 | - | $2.33B(+8.0%) |
| Jun 1993 | - | $2.15B(+32.9%) |
| Mar 1993 | - | $1.62B(-24.1%) |
| Dec 1992 | - | $2.14B(+121.0%) |
| Sep 1992 | - | $967.00M(+18.8%) |
| Jun 1992 | - | $814.00M(-30.5%) |
| Mar 1992 | - | $1.17B(-18.3%) |
| Dec 1991 | - | $1.44B(+10.4%) |
| Sep 1991 | - | $1.30B(+19.4%) |
| Jun 1991 | - | $1.09B(+79.1%) |
| Mar 1991 | - | $608.00M(+2.0%) |
| Dec 1990 | $1.96B(+163.4%) | $596.00M(-48.6%) |
| Sep 1990 | - | $1.16B(-5.0%) |
| Jun 1990 | - | $1.22B(+30.7%) |
| Mar 1990 | - | $934.00M(+83.1%) |
| Dec 1989 | - | $510.00M(-79.7%) |
| Dec 1988 | - | $2.51B(+7.0%) |
| Dec 1987 | - | $2.35B |
| Dec 1983 | $743.40M(+21.6%) | - |
| Dec 1982 | $611.60M(+42.5%) | - |
| Dec 1981 | $429.30M | - |
FAQ
- What is Bristol-Myers Squibb Company annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Bristol-Myers Squibb Company?
- What is Bristol-Myers Squibb Company annual cash & cash equivalents year-on-year change?
- What is Bristol-Myers Squibb Company quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Bristol-Myers Squibb Company?
- What is Bristol-Myers Squibb Company quarterly cash & cash equivalents year-on-year change?
What is Bristol-Myers Squibb Company annual cash & cash equivalents?
The current annual cash & cash equivalents of BMY is $10.86B
What is the all time high annual cash & cash equivalents for Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company all-time high annual cash & cash equivalents is $17.36B
What is Bristol-Myers Squibb Company annual cash & cash equivalents year-on-year change?
Over the past year, BMY annual cash & cash equivalents has changed by -$1.48B (-11.97%)
What is Bristol-Myers Squibb Company quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of BMY is $13.62B
What is the all time high quarterly cash & cash equivalents for Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company all-time high quarterly cash & cash equivalents is $32.54B
What is Bristol-Myers Squibb Company quarterly cash & cash equivalents year-on-year change?
Over the past year, BMY quarterly cash & cash equivalents has changed by +$6.96B (+104.61%)